share_log

Amgen | 8-K: AMGEN REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS

Amgen | 8-K: AMGEN REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS

安進 | 8-K：安進公佈2024年第二季度財務業績
美股SEC公告 ·  2024/08/07 04:10

Moomoo AI 已提取核心訊息

Amgen reported strong Q2 2024 financial results with total revenues increasing 20% to $8.4 billion, driven by 26% volume growth partially offset by 3% lower net selling price. Product sales grew 20% to $8.0 billion, including $1.1 billion from rare disease products. Twelve products achieved double-digit sales growth, including Prolia, EVENITY, Repatha, and TEZSPIRE.GAAP earnings per share decreased 46% to $1.38, impacted by higher operating expenses including Horizon-related amortization. Non-GAAP EPS declined slightly by 1% to $4.97. Operating margin decreased to 23.7% GAAP and 48.2% non-GAAP. The company generated $2.2 billion in free cash flow.The company maintained its full-year 2024 guidance with total revenues expected between $32.8-33.8 billion. GAAP EPS is projected at $6.57-7.62 and non-GAAP EPS at $19.10-20.10. Amgen remains on track to achieve over $10 billion in debt reduction by end of 2025, having reduced debt by $2.0 billion year-to-date.
Amgen reported strong Q2 2024 financial results with total revenues increasing 20% to $8.4 billion, driven by 26% volume growth partially offset by 3% lower net selling price. Product sales grew 20% to $8.0 billion, including $1.1 billion from rare disease products. Twelve products achieved double-digit sales growth, including Prolia, EVENITY, Repatha, and TEZSPIRE.GAAP earnings per share decreased 46% to $1.38, impacted by higher operating expenses including Horizon-related amortization. Non-GAAP EPS declined slightly by 1% to $4.97. Operating margin decreased to 23.7% GAAP and 48.2% non-GAAP. The company generated $2.2 billion in free cash flow.The company maintained its full-year 2024 guidance with total revenues expected between $32.8-33.8 billion. GAAP EPS is projected at $6.57-7.62 and non-GAAP EPS at $19.10-20.10. Amgen remains on track to achieve over $10 billion in debt reduction by end of 2025, having reduced debt by $2.0 billion year-to-date.
安進發佈了強勁的2024年第二季度財務業績，總收入增長20%，達到84億美金，主要受26%成交量增長的推動，部分被3%的淨銷售價格下降所抵消。產品銷售增長20%，達到80億美金，其中來自罕見疾病產品的收入爲11億美金。十二種產品實現了兩位數的銷售增長，包括Prolia、EVENITY、Repatha和TEZSPIRE。GAAP 每股收益下降46%，至1.38美金，受較高的營業費用影響，包括與Horizon相關的攤銷。非GAAP 每股收益略微下降1%，達到4.97美金。營業利潤率下降至23.7% GAAP和48.2%非GAAP。公司創造了22億美金的自由現金流。公司維持2024年全年的指引，預計總收入將在328-338億美金之間。GAAP 每股收益預計在6.57-7.62美金之間，非GAAP 每股收益預計在19.10-20.10美金之間。安進仍在計劃內，預計到2025年底實現超過100億美金的減債，年初至今已減少債務20億美金。
安進發佈了強勁的2024年第二季度財務業績，總收入增長20%，達到84億美金，主要受26%成交量增長的推動，部分被3%的淨銷售價格下降所抵消。產品銷售增長20%，達到80億美金，其中來自罕見疾病產品的收入爲11億美金。十二種產品實現了兩位數的銷售增長，包括Prolia、EVENITY、Repatha和TEZSPIRE。GAAP 每股收益下降46%，至1.38美金，受較高的營業費用影響，包括與Horizon相關的攤銷。非GAAP 每股收益略微下降1%，達到4.97美金。營業利潤率下降至23.7% GAAP和48.2%非GAAP。公司創造了22億美金的自由現金流。公司維持2024年全年的指引，預計總收入將在328-338億美金之間。GAAP 每股收益預計在6.57-7.62美金之間，非GAAP 每股收益預計在19.10-20.10美金之間。安進仍在計劃內，預計到2025年底實現超過100億美金的減債，年初至今已減少債務20億美金。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Medicus Pharma
    MDCX
    -- 3.720
    Organon & Co
    OGN
    -- 14.890
    Scilex Holding
    SCLX
    -- 0.249
    艾伯維公司
    ABBV
    -- 209.520
    諾和諾德
    NVO
    -- 69.440
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    FOMC維持利率但不確定性高企：美股後市走向如何？
    🎙️討論 1. 美聯儲強調政策路徑存在「高度不確定性」，你更關注利率預期變化還是經濟數據對市場的短期影響？ 2. 若核心通脹維持高位，哪類板塊更具交易機會——防禦型股票還是科技成長股？ 展开
    聯邦公開市場委員會新聞發佈會，2025年3月19日